Unadjusted and Adjusted Relative Risk of Serious Adverse Events and Diagnosed COVID-19 in the 28 Days Following the Week of the First Dose of mRNA-1273 Compared to BNT162b2 Vaccines Among Community-Dwelling Medicare Beneficiaries Categorized as Nonfrail in the US (December 2020 to July 2021)ĮTable 6. Unadjusted and Adjusted Relative Risk of Serious Adverse Events and Diagnosed COVID-19 in the 28 Days Following the Week of the First Dose of mRNA-1273 Compared to BNT162b2 Vaccines Among Community-Dwelling Medicare Beneficiaries in the US (December 2020 to July 2021)ĮTable 5. Risk of Serious Adverse Events and Diagnosed COVID-19 in the 28 Days Following the Week of the First Dose of mRNA-1273 or BNT162b2 Vaccines Among Community-Dwelling Medicare Fee-for-Service Beneficiaries in the US (December 2020 to July 2021)ĮTable 4. Participant Loss to Follow-up in the 28 Days Following the Week of the First Dose of an mRNA Vaccine Against COVID-19 (December 2020 to July 2021)ĮTable 3. ICD-10-CM Diagnosis Codes Used to Define the Serious Adverse Event Outcomes in This StudyĮTable 2. The nonfrail estimates for facial nerve palsy and prefrail estimates for thrombocytopenia purpura are the same due to rounding.ĮTable 1. Risk ratios are interpreted as the relative difference in the outcome between mRNA-1273 vs BNT162b2 within each frailty subgroup, whereby an RR of 1.00 represents no relative difference in risk within that frailty subgroup. Model 1 was unadjusted model 4 was adjusted for region, month of vaccination, age, sex, race and ethnicity, claim source (eg, pharmacy and/or Medicare), time since prior documented COVID-19 infection, time since prior hospitalization, time since prior outpatient visit, and time since prior emergency department visit. Interaction terms between frailty subgroup and vaccine type were included to obtain stratum-specific estimates and to formally test for modification (interaction term: P < .05). A to D, Risk ratios (RRs) and 95% CIs for facial nerve palsy (A), thrombocytopenia purpura (B), pulmonary embolism (C), and myocarditis or pericarditis (D) were estimated using generalized linear models with a binominal distribution and log link function.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |